Growth & profitability
- Revenue has declined 55.6% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
TRDA Financials Entrada Therapeutics, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $25M | -$144M | 0.0% | -621.1% | -$130M | — | $90M |
| 2024 | $211M | $66M | 0.0% | 22.3% | -$45M | — | $101M |
| 2023 | $129M | -$7M | 0.0% | -2.5% | $134M | — | $68M |
| 2022 | — | -$95M | — | — | -$97M | — | $45M |
| 2021 | — | -$51M | — | — | -$55M | — | $291M |
| 2020 | — | -$27M | — | — | -$28M | — | $39M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $875000 | -$40M | 0.0% | -4834.6% | -$42M | — | $76M |
| Dec '25 | $1M | -$39M | 0.0% | -3249.3% | -$32M | — | $90M |
| Sep '25 | $2M | -$44M | 0.0% | -2915.2% | -$28M | — | $93M |
| Jun '25 | $2M | -$43M | 0.0% | -2402.5% | -$30M | — | $72M |
| Mar '25 | $21M | -$17M | 0.0% | -106.0% | -$40M | — | $68M |
| Dec '24 | $37M | $1M | 0.0% | -15.7% | -$32M | — | $101M |
| Sep '24 | $20M | -$14M | 0.0% | -110.7% | -$25M | — | $78M |
| Jun '24 | $95M | $55M | 0.0% | 56.4% | $39M | — | $185M |
| Mar '24 | $59M | $23M | 0.0% | 35.7% | -$26M | — | $68M |
| Dec '23 | $42M | -$10M | 0.0% | 11.7% | -$5M | — | $68M |
| Sep '23 | $44M | $35M | 0.0% | 32.0% | -$26M | — | $52M |
| Jun '23 | $18M | -$26M | 0.0% | -89.7% | -$37M | — | $80M |
| Mar '23 | $25M | -$7M | 0.0% | -22.9% | $202M | — | $228M |
| Dec '22 | — | -$25M | — | — | -$28M | — | $45M |
| Sep '22 | $0 | -$25M | — | — | -$28M | — | $53M |
| Jun '22 | $0 | -$23M | — | — | -$19M | — | $91M |
| Mar '22 | $0 | -$22M | — | — | -$22M | — | $85M |
| Dec '21 | — | -$18M | — | — | -$22M | — | $291M |
| Sep '21 | — | -$14M | — | — | -$15M | — | $122M |
| Jun '21 | — | -$10M | — | — | -$9M | — | — |
Valuation over time
How the market has priced TRDA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 10.2× (Dec '24) to 6.1× (Nov '25).
- The price-to-sales ratio has risen from 4.4× (Jan '24) to 10.9× (Jun '26).
P/E
P/S
Frequently asked questions
Is TRDA growing its revenue and profit?
Over the past 5 years, Entrada Therapeutics, Inc.'s revenue has declined 55.6% per year. These are computed facts, not advice.
How much debt does TRDA have?
As of FY2025, Entrada Therapeutics, Inc. reported — of total debt against $90M of cash.
What is TRDA's profit margin?
In FY2025, gross margin was —, operating margin -621.1%, and net margin -565.5%.
What is TRDA's P/E ratio?
As of Jun '26, Entrada Therapeutics, Inc. traded at a price-to-earnings ratio of about 6.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.